ES2074429T3 - Derivados de fluorocitidina, su preparacion y preparados medios que los contienen. - Google Patents

Derivados de fluorocitidina, su preparacion y preparados medios que los contienen.

Info

Publication number
ES2074429T3
ES2074429T3 ES88118515T ES88118515T ES2074429T3 ES 2074429 T3 ES2074429 T3 ES 2074429T3 ES 88118515 T ES88118515 T ES 88118515T ES 88118515 T ES88118515 T ES 88118515T ES 2074429 T3 ES2074429 T3 ES 2074429T3
Authority
ES
Spain
Prior art keywords
derivatives
fluorocitidine
contain
preparation
prepared means
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88118515T
Other languages
English (en)
Inventor
Morio Fujiu
Hideo Ishitsuka
Masanori Miwa
Isao Imperial Higashihak Umeda
Kazuteru Yokose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2074429T3 publication Critical patent/ES2074429T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

LOS DERIVADOS DE 5 - DEOXI - 5 - FLUORCITIDINA DE FORMULA GENERAL(I) DONDE R1, R2 Y R3 SON, INDEPENDIENTEMENTE, H O UN GRUPO FACILMENTE SEPARABLE BAJO CONDICIONES FISIOLOGICAS, CON LA CONDICION DE QUE AL MENOS UNO DE LOS RESTOS R1, R2 Y R3 SEA UN GRUPO FACILMENTE SEPARABLE BAJO CONDICIONES FISIOLOGICAS, ASI COMO HIDRATOS O SOLVATOS DE ESTOS COMPUESTOS TIENEN EFECTO ANTITUMORAL. SE PUEDEN OBTNER PARTIENDO DE COMPUESTOS CORRESPONDIENTES DE LA FORMULA I, DONDE R1, R2 Y R3 REPRESENTAN H, O GRUPOS PROTECTORES DE N U O.
ES88118515T 1987-11-17 1988-11-07 Derivados de fluorocitidina, su preparacion y preparados medios que los contienen. Expired - Lifetime ES2074429T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP87116926 1987-11-17

Publications (1)

Publication Number Publication Date
ES2074429T3 true ES2074429T3 (es) 1995-09-16

Family

ID=8197450

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88118515T Expired - Lifetime ES2074429T3 (es) 1987-11-17 1988-11-07 Derivados de fluorocitidina, su preparacion y preparados medios que los contienen.

Country Status (35)

Country Link
US (1) US4966891A (es)
EP (1) EP0316704B1 (es)
JP (1) JPH0678350B2 (es)
KR (1) KR970000241B1 (es)
CN (1) CN1022688C (es)
AR (1) AR247217A1 (es)
AT (1) ATE124951T1 (es)
AU (1) AU619220B2 (es)
CA (1) CA1327358C (es)
CS (1) CS274486B2 (es)
DE (2) DE10199027I2 (es)
DK (1) DK170893B1 (es)
DZ (1) DZ1270A1 (es)
ES (1) ES2074429T3 (es)
FI (1) FI89804C (es)
GR (1) GR3017686T3 (es)
HK (1) HK1003114A1 (es)
HU (1) HU199866B (es)
IE (1) IE883430L (es)
IL (1) IL88363A0 (es)
IS (1) IS1895B (es)
LT (1) LT2185B (es)
LU (1) LU90769I2 (es)
LV (1) LV5624A3 (es)
MC (1) MC1992A1 (es)
MX (1) MX173347B (es)
NL (1) NL300045I2 (es)
NO (2) NO171167C (es)
NZ (1) NZ226923A (es)
PH (1) PH25641A (es)
PT (1) PT89009B (es)
SU (1) SU1736342A3 (es)
UA (1) UA19333A (es)
YU (1) YU47122B (es)
ZA (1) ZA888428B (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258360B1 (en) * 1989-05-04 2001-07-10 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
TW254946B (es) * 1992-12-18 1995-08-21 Hoffmann La Roche
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20010051348A1 (en) * 2000-01-28 2001-12-13 Lee Chee Wee Novel ligands and methods for preparing same
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US6774758B2 (en) * 2002-09-11 2004-08-10 Kalyan P. Gokhale Low harmonic rectifier circuit
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
CA2525973A1 (en) * 2003-05-20 2004-12-09 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising capecitabine and a liposomal platinum complex
DE602004015331D1 (de) * 2003-12-22 2008-09-04 Hoffmann La Roche Verfahren für fluorcytidinderivate
ES2322709T3 (es) * 2004-02-18 2009-06-25 Astrazeneca Ab Derivados de benzamida y su uso como agentes activadores de la glucocinasa.
WO2005080360A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Compounds
CN100383128C (zh) * 2004-02-23 2008-04-23 上海迪赛诺医药发展有限公司 N4－氧羰基胞嘧啶衍生物及制备方法与应用
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR101061850B1 (ko) 2004-09-08 2011-09-02 삼성전자주식회사 박막 트랜지스터 표시판 및 그 제조방법
GB0421294D0 (en) * 2004-09-24 2004-10-27 Angiogene Pharm Ltd Bioreductively-activated prodrugs
WO2006040527A1 (en) 2004-10-16 2006-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
NO322682B1 (no) * 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
EP1868608A2 (en) * 2005-04-01 2007-12-26 F. Hoffmann-Roche AG Method for administration of capecitabine
US20110059941A1 (en) * 2005-05-24 2011-03-10 Peter William Rodney Caulkett 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
US20110053910A1 (en) * 2005-07-09 2011-03-03 Mckerrecher Darren 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
KR20110084339A (ko) 2005-07-09 2011-07-21 아스트라제네카 아베 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체
US20080234273A1 (en) * 2005-07-09 2008-09-25 Mckerrecher Darren Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes
CN100569790C (zh) * 2005-07-15 2009-12-16 上海奥锐特国际贸易有限公司 合成n4-酰基-5＇-脱氧-5-氟胞苷衍生物的方法
EP1906977B1 (en) * 2005-07-21 2012-02-22 Nuvo Research AG Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment.
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
CL2007003061A1 (es) 2006-10-26 2008-08-01 Astrazeneca Ab Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
AU2007336016A1 (en) 2006-12-21 2008-06-26 Astrazeneca Ab Novel crystalline compound useful as GLK activator
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
MX2009011255A (es) * 2007-04-20 2009-11-23 Reddys Lab Ltd Dr Proceso para preparar capecitabina.
EP2164856A1 (en) * 2007-06-01 2010-03-24 Synthon B.V. Processes related to making capecitabine
WO2009042064A2 (en) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US20090209754A1 (en) * 2008-01-03 2009-08-20 Macdonald Peter Lindsay Process for the preparation of capecitabine
RU2492860C2 (ru) 2008-06-17 2013-09-20 УАЙТ ЭлЭлСи Антиопластические комбинации, содержащие нкi-272 и винорелбин
PL3175853T3 (pl) 2008-08-04 2024-03-25 Wyeth Llc Przeciwnowotworowe połączenia neratynibu i kapecytabiny
CN102171213A (zh) 2008-08-04 2011-08-31 阿斯利康(瑞典)有限公司 吡唑并[3，4]嘧啶-4-基衍生物及其治疗糖尿病和肥胖症的用途
EP2370414A4 (en) * 2008-12-02 2012-11-14 Reddys Lab Ltd Dr PREPARATION OF CAPECITABINE
EP2393472B1 (en) * 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
CN101787066B (zh) * 2009-01-23 2013-07-31 高峰 阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
PL3000467T3 (pl) 2009-04-06 2023-05-02 Wyeth Llc Schemat leczenia wykorzystujący neratynib dla raka sutka
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
CN101875680B (zh) * 2009-04-28 2012-07-25 上海信旗医药科技有限公司 一种核苷类化合物及其制备方法和应用
WO2011010967A1 (en) * 2009-07-23 2011-01-27 Scinopharm Taiwan Ltd. Process for producing flurocytidine derivatives
ES2584433T3 (es) 2010-03-12 2016-09-27 Genzyme Corporation Terapia de combinación para tratar cáncer de mama
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
CA2868391A1 (en) 2012-04-02 2013-10-10 Stephane Bancel Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
KR102281288B1 (ko) 2012-09-26 2021-07-26 에프. 호프만-라 로슈 아게 환형 에터 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 이의 사용 방법
JP2015536954A (ja) * 2012-11-07 2015-12-24 ズカイ スオ 置換ゲムシタビンアリールアミド類似体
EP3578663A1 (en) 2013-03-15 2019-12-11 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
US10000521B2 (en) 2013-03-15 2018-06-19 Nucorion Pharmaceuticals, Inc. Substituted gemcitabine bicyclic amide analogs and treatment methods using same
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
CN103450301B (zh) * 2013-09-09 2015-09-09 南通大学 法尼基硫代水杨酸-核苷缀合物、其制备方法及其医药用途
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
JP6950972B2 (ja) * 2016-06-28 2021-10-20 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ ガンの処置のための組成物及び方法
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP4046989A1 (en) 2017-01-09 2022-08-24 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2018200859A1 (en) 2017-04-26 2018-11-01 Kalman Thomas I Multitargeted nucleoside derivatives
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
EP3737376B1 (en) 2018-01-09 2024-04-17 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human diseases
WO2019143860A1 (en) * 2018-01-19 2019-07-25 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
KR20210057025A (ko) * 2018-08-03 2021-05-20 셀릭스 바이오 프라이빗 리미티드 암의 치료를 위한 조성물 및 방법
CN109651467A (zh) * 2019-01-15 2019-04-19 齐鲁天和惠世制药有限公司 一种卡培他滨杂质及其制备方法
WO2021216427A1 (en) 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds
WO2022020811A1 (en) 2020-07-24 2022-01-27 Strand Therapeutics, Inc. Lipidnanoparticle comprising modified nucleotides
JP2024503000A (ja) 2021-01-08 2024-01-24 ストランド セラピューティクス インコーポレイテッド 発現構築物およびその使用
WO2023212618A1 (en) 2022-04-26 2023-11-02 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3404144A (en) * 1965-12-23 1968-10-01 Research Corp 1-beta-d-arabinofuranosyl-5-fluorocytosine compounds
GB1379410A (en) * 1971-06-08 1975-01-02 Upjohn Co 1-beta-d-arabino-furanosyl-n4-alpha-aminoacylcytosines
JPS52153977A (en) * 1976-06-11 1977-12-21 Daikin Ind Ltd Synthesis of 5-fluorouracil and its derivatives
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
CH633810A5 (en) * 1978-01-01 1982-12-31 Hoffmann La Roche Novel nucleosides and process for their preparation
FR2528311B1 (fr) * 1982-06-14 1985-06-14 Synthelabo Compositions pharmaceutiques a base de xylosides et lyxosides de bases puriques et pyrimidiques
JPS61112093A (ja) * 1984-11-05 1986-05-30 Wakunaga Seiyaku Kk ヌクレオチド誘導体

Also Published As

Publication number Publication date
PT89009A (pt) 1988-12-01
CN1033183A (zh) 1989-05-31
UA19333A (uk) 1997-12-25
GR3017686T3 (en) 1996-01-31
DE3854148D1 (de) 1995-08-17
KR890008162A (ko) 1989-07-10
IE883430L (en) 1989-05-17
AR247217A1 (es) 1994-11-30
NL300045I2 (nl) 2002-01-02
EP0316704A3 (en) 1990-11-22
SU1736342A3 (ru) 1992-05-23
FI89804C (fi) 1993-11-25
DK640388D0 (da) 1988-11-16
HU199866B (en) 1990-03-28
KR970000241B1 (ko) 1997-01-08
DE10199027I2 (de) 2002-01-31
IS3412A7 (is) 1989-05-18
FI89804B (fi) 1993-08-13
LU90769I2 (fr) 2001-07-02
IS1895B (is) 2003-10-20
LT2185B (lt) 1993-10-15
FI885329A (fi) 1989-05-18
AU619220B2 (en) 1992-01-23
JPH01153696A (ja) 1989-06-15
PT89009B (pt) 1993-02-26
YU209188A (en) 1990-08-31
DE10199027I1 (de) 2001-08-02
CN1022688C (zh) 1993-11-10
NO2001013I2 (no) 2006-05-01
MX13836A (es) 1993-10-01
CA1327358C (en) 1994-03-01
NO885106L (no) 1989-05-18
LV5624A3 (lv) 1994-05-10
MC1992A1 (fr) 1989-11-30
NO885106D0 (no) 1988-11-16
DK170893B1 (da) 1996-03-04
NL300045I1 (nl) 2001-08-01
PH25641A (en) 1991-08-21
CS274486B2 (en) 1991-04-11
ATE124951T1 (de) 1995-07-15
EP0316704A2 (de) 1989-05-24
NZ226923A (en) 1990-10-26
DK640388A (da) 1989-05-18
US4966891A (en) 1990-10-30
MX173347B (es) 1994-01-03
YU47122B (sh) 1994-12-28
HUT48267A (en) 1989-05-29
FI885329A0 (fi) 1988-11-17
EP0316704B1 (de) 1995-07-12
DZ1270A1 (fr) 2004-09-13
CS747588A2 (en) 1990-09-12
ZA888428B (en) 1989-06-28
NO171167C (no) 1993-02-03
NO171167B (no) 1992-10-26
AU2516888A (en) 1989-05-25
IL88363A0 (en) 1989-06-30
HK1003114A1 (en) 1998-10-09
JPH0678350B2 (ja) 1994-10-05

Similar Documents

Publication Publication Date Title
ES2074429T3 (es) Derivados de fluorocitidina, su preparacion y preparados medios que los contienen.
ES2150918T3 (es) 1h-imidazo(4,5-c)quinolin-4-aminas 1-sustituidas; compuestos intermedios y composiciones farmaceuticas.
JPS5412381A (en) N-alkylpiperidine derivative
AT370763B (de) Kohlensuspension, enthaltend pulverisierte kohle, wasser und dispergierungsmittel, sowie verfahren zur herstellung derselben
FI874975A (fi) Antioxidanta kompositioner och foerfarande foer deras framstaellning.
MX9305805A (es) Aroiloxicarboxamidas yodados.
ES2009785B3 (es) Procedimiento para preparar derivados de tioxantona.
ES2059416T3 (es) 1,4-dihidropiridina-enantiomeros.
MX168030B (es) Procedimiento para la preparacion de derivados de alcano y alcoxialcano
ATE40358T1 (de) 2,3-dihydrobenzofuran-derivate, mehrere verfahren zu ihrer herstellung und sie enthaltende arzneimittel.
ES2043725T3 (es) Aminofenil-carbamatos substituidos.
ES471530A1 (es) Procedimiento para la preparacion de fosfonitas
ES2095068T3 (es) Peroxicarbonatos polimericos y procedimiento para prepararlos.
GR64937B (en) Method for the preparation of derivatives of benzimidazole which containing sulphur
ES2057322T3 (es) Derivados de amida de aminoacido substituidos, su fabricacion y uso.
ES2075004T3 (es) Derivados de pirimidina, procedimientos para su produccion y composiciones herbicidas que los contienen.
ES2062202T3 (es) Derivado del indol.
NO803245L (no) Fremgangsmaate ved fremstilling av cyclisk hexapeptid somatostatinanaloger.
DK92388D0 (da) Diorganopolysiloxangruppeholdige disubstituerede n,n'-bis-maleimider samt fremgangsmaade til fremstilling deraf
FI871066A (fi) Anordning foer begraensning av den vertikala fjaedringen av en axelkropp.
ES470274A1 (es) Procedimiento de preparacion de nuevos derivados de benzo- (b)-tienopiridinas
FR2303810A1 (fr) Phosphonates utilisables pour la stabilisation de matieres organiques sensibles aux degradations thermo-oxydatives
DK471686D0 (da) Tetrahydro-beta-carboliner, fremgangsmaade til deres fremstilling og deres anvendelse som laegemiddel
ES2036583T3 (es) Iminooxazolidinas, procedimiento de preparacion y metodo de uso.
DK0457215T3 (da) 3-deamino-4-desoxy-4-amino-8-fluoranthracycliner samt fremgangsmåder til fremstilling deraf

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 316704

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: CAPECITABINE (XELODA)

Spc suppl protection certif: C200100017

Filing date: 20010628

SPCG Supplementary protection certificate granted

Free format text: CAPECITABINE (XELODA)

Spc suppl protection certif: C200100017

Filing date: 20010628

Expiry date: 20131107

Effective date: 20031211